Detlef Stiller1, Thomas Kaulisch1, Selina Bucher1, Julia Tillmanns1, David Kind1, Heiko G. Niessen1, Krisztina Rona-Vrs2, Kerstin E. Braunstein2, Hans-Peter Mller2, Luc Dupuis3, Albert C. Ludolph2
1In-Vivo Imaging, Dept. of Drug Discovery Support, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, BW, Germany; 2Dept. of Neurology, University of Ulm, Ulm, BW, Germany; 3ISERM U692, Strasbourg, France
A mouse with a point mutation in the gene encoding the motorprotein dynein is characterized by abnormal reflexes and by progressive motor and behavioral abnormalities without motor neuron degeneration. Even though previous studies showed age-dependent striatal astrocytosis and dysfunction, no in-vivo characterization of the brain has been performed yet. To investigate structural and functional alterations in the mouse brain, longitudinal MRI and [18F]-Fallypride PET were performed. In mutant mice the striatum size was significantly decreased, that of the ventricles significantly increased. PET imaging revealed a significantly reduced striatal uptake of Fallypride, supporting the theory of cell loss in the structure.